 TEL AVIV, Israel and RALEIGH, NC, July 19, 2021 PRNewswire -- RedHill Biopharma Ltd. Nasdaq: RDHL RedHill or the Company, a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 23 study with opaganib ABC2946401 in patients hospitalized with severe COVID-19 pneumonia NCT04467840. 